Table 1. Patient characteristics at diagnosis.
| Variable | n (%) | |
| Age | Median (range) | 62 (36–78) |
| ≥65 yr | 25 (35) | |
| <65 yr | 46 (65) | |
| Gender | Male | 40 (56) |
| Female | 31 (44) | |
| Performance status | 0 | 3 (4) |
| 1 | 39 (55) | |
| 2 | 29 (41) | |
| Sites of biopsy | Lymphnodes | 38 (54) |
| Bone or Bone marrow | 10 (14) | |
| Liver | 6 (9) | |
| Gastrointestinal tract | 4 (6) | |
| Skin | 2 (3) | |
| Adrenal gland | 2 (3) | |
| Others | 8 (10) | |
| Bone metastasis | Yes | 13 (18) |
| No | 58 (82) | |
| Liver metastasis | Yes | 6 (9) |
| No | 65 (91) | |
| Lung metastasis | Yes | 12 (17) |
| No | 59 (83) | |
| Lymph node metastasis | No | 18 (25) |
| Yes | 53 (75) | |
| Treatment regimen | Cisplatin or carboplatin/docetaxel | 16 (22) |
| Carboplatin/irinotecan | 22 (31) | |
| Carboplatin/paclitaxel | 29 (41) | |
| Carboplatin/S1 or FOLFOX | 4 (6) | |
FOLFOX: 5FU, oxaliplatin, and l-leukovorin.